These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 19342201)
1. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension. Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K J Dermatol Sci; 2009 Jul; 55(1):66-7. PubMed ID: 19342201 [No Abstract] [Full Text] [Related]
2. Bosentan therapy for pulmonary arterial hypertension. Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289 [TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis. Nishibu A; Sakai E; Oyama N; Yamamoto T Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581 [TBL] [Abstract][Full Text] [Related]
4. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Hachulla E; Coghlan JG Ann Rheum Dis; 2004 Sep; 63(9):1009-14. PubMed ID: 15308510 [TBL] [Abstract][Full Text] [Related]
5. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis. Varga J Curr Rheumatol Rep; 2003 Apr; 5(2):145-6. PubMed ID: 12628045 [No Abstract] [Full Text] [Related]
6. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Ahmadi-Simab K; Hellmich B; Gross WL Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010 [TBL] [Abstract][Full Text] [Related]
7. N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. Dimitroulas T; Giannakoulas G; Karvounis H; Dimitroula H; Settas L Rheumatol Int; 2009 Jan; 29(3):347-8. PubMed ID: 18690444 [No Abstract] [Full Text] [Related]
8. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188 [TBL] [Abstract][Full Text] [Related]
9. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Sharma S; Kashour T; Philipp R Tex Heart Inst J; 2005; 32(3):405-10. PubMed ID: 16392231 [TBL] [Abstract][Full Text] [Related]
10. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199 [TBL] [Abstract][Full Text] [Related]
11. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Denton CP; Humbert M; Rubin L; Black CM Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845 [TBL] [Abstract][Full Text] [Related]
13. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. McLaughlin VV Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005 [TBL] [Abstract][Full Text] [Related]
14. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension]. MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438 [No Abstract] [Full Text] [Related]
15. [Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis]. Shalev L; Langevitz P; Zandman-Goddard G Harefuah; 2008 Apr; 147(4):287-9, 376. PubMed ID: 18686806 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]